THE ROLE OF DIFFERENT FACTORS IN THE DEVELOPMENT OF COMPLICATIONS OF GASTRIC AND DUODENAL PEPTIC ULCER DISEASE
Keywords:
peptic ulcer disease, gastric ulcer, duodenal ulcer, complications, gastrointestinal bleeding, perforation, penetration, stenosis, Helicobacter pylori, NSAIDs, risk factors.Abstract
Peptic ulcer disease (PUD) of the stomach and duodenum remains an important clinical problem despite significant advances in the diagnosis and treatment of gastrointestinal diseases. The clinical significance of PUD is determined not only by its prevalence and recurrent course but also by the possibility of developing severe complications, including gastroduodenal bleeding, perforation, penetration, and pyloroduodenal stenosis [1,2]. These complications are associated with increased morbidity, prolonged hospitalization, the need for endoscopic or surgical treatment, and an increased risk of mortality.
The development of complications of PUD is multifactorial. The most important risk factors include Helicobacter pylori infection, the use of non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid, anticoagulants and antiplatelet agents, smoking, alcohol consumption, advanced age, severe comorbidities, previous ulcer disease and gastrointestinal bleeding, as well as the characteristics of the ulcer itself [3–6]. The interaction between several risk factors may substantially increase the probability of complications.
The highest risk of ulcer-related bleeding and perforation is observed in elderly patients, particularly those receiving NSAIDs, aspirin or antithrombotic therapy and those with cardiovascular or renal comorbidities [6,8]. Therefore, modern management of PUD requires not only treatment of the ulcerative defect but also comprehensive assessment of individual risk factors and preventive measures.
References
1.Ivashkin V.T., Maev I.V., Lapina T.L., et al. Clinical guidelines of the Russian Gastroenterological Association for the diagnosis and treatment of peptic ulcer disease // Russian Journal of Gastroenterology, Hepatology and Coloproctology. — 2016. — Vol. 26, No. 6. — P. 40–61.
2.Lazebnik L.B., Bordin D.S., Masharova A.A., et al. Peptic ulcer disease: modern approaches to diagnosis and treatment // Experimental and Clinical Gastroenterology. — 2016. — No. 2. — P. 3–12.
3.Maev I.V., Samsonov A.A., Andreev D.N. Peptic ulcer disease: modern concepts of etiology, pathogenesis, diagnosis and treatment // Medical Council. — 2018. — No. 14. — P. 54–62.
4.Trukhan D.I., Tarasova L.V. Modern approaches to the diagnosis and treatment of Helicobacter pylori infection // Medical Council. — 2019. — No. 14. — P. 84–91.
5.Tkachenko E.I., Sitkin S.I. Non-steroidal anti-inflammatory drugs and diseases of the upper gastrointestinal tract: current aspects of the problem // Experimental and Clinical Gastroenterology. — 2014. — No. 8. — P. 3–10.
6.Barkun A.N., Almadi M., Kuipers E.J., et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group // Annals of Internal Medicine. — 2019. — Vol. 171, No. 11. — P. 805–822.
7.Laine L., Barkun A.N., Saltzman J.R., et al. ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding // American Journal of Gastroenterology. — 2021. — Vol. 116, No. 5. — P. 899–917.
8.Lau J.Y.W., Sung J., Hill C., Henderson C., Howden C.W., Metz D.C. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality // Digestive and Liver Disease. — 2011. — Vol. 43, No. 1. — P. 1–8.
9.Lanas A., Chan F.K.L. Peptic ulcer disease // The Lancet. — 2017. — Vol. 390, No. 10094. — P. 613–624.
10.Straube S., Tramèr M.R., Moore R.A., Derry S. Mortality with upper gastrointestinal bleeding and perforation associated with non-steroidal anti-inflammatory drugs: meta-analysis of observational studies // Journal of Clinical Epidemiology. — 2009. — Vol. 62, No. 10. — P. 1007–1016.
11.Valkhoff V.E., Sturkenboom M.C.J.M., Kuipers E.J. Risk factors for gastrointestinal bleeding associated with low-dose aspirin // Best Practice & Research Clinical Gastroenterology. — 2012. — Vol. 26, No. 2. — P. 125–140.
12.Wei L., Jørgensen J., Wang Y., et al. Analysis of risk factors affecting the development of peptic ulcer perforation: case-control study // Prz Gastroenterol. — 2021. — Vol. 16, No. 4. — P. 325–331.